NanoVation Therapeutics™
David Broemeling currently serves as the Vice President of Operations at NanoVation Therapeutics™ and holds the position of Associate Mentor at the Creative Destruction Lab. Prior to these roles, David was the Director of Business Development at Natera from September 2021 to August 2023. David co-founded Boreal Genomics, where responsibilities included Vice President of Marketing & Business Development, Director of Marketing, and Director of Operations from July 2007 to September 2021. Earlier in the career, David worked as a Scientific Engineer and Lab Manager at The University of British Columbia from 2004 to 2010. David earned a Bachelor of Applied Science in Engineering Physics (Electrical) from The University of British Columbia from 1998 to 2003.
This person is not in the org chart
This person is not in any teams
NanoVation Therapeutics™
NanoVation Therapeutics is a pioneer in the design and creation of lipid nanoparticles (LNPs) for nucleic acid delivery. The company’s LNP technologies aim to overcome the limitations of existing nucleic acid delivery approaches, including the ability to target tissues outside the liver (extrahepatic delivery). NanoVation’s lead technology is its proprietary long-circulating LNP (lcLNP™) platform, which enables functional nucleic acid delivery to extrahepatic cell types and has demonstrated an improved therapeutic index in preclinical studies. NanoVation partners with leading pharmaceutical and biotech companies develop genetic medicines for previously untreatable diseases. NTx is delivering tomorrow's genetic medicines, today. For more information, please visit nanovationtx.com.